FDA intends to take action against non-FDA-approved GLP-1 drugs

Compounding GLP‑1s, Patents, and FDA Enforcement

• Many comments say this crackdown was inevitable: compounding pharmacies and telehealth brands scaled from niche “shortage exceptions” into mass‑market alternatives that clearly undercut patent holders.
• Others argue these firms were “blatantly skirting” patent law and FDA rules and should have expected enforcement once official shortages ended.
• A counterview sees compounders as providing a public good during ongoing de‑facto shortages and unaffordable pricing, and views the FDA’s move as protecting incumbents’ profits more than safety.

Pricing, IP Incentives, and “Free Riding”

• One camp defends strong drug patents: GLP‑1s cost billions and decades to develop; if copycats can sell cheaply during exclusivity, future breakthrough drugs won’t be funded.
• Another camp is openly hostile to IP, especially “evergreening” via formulation/delivery patents, and says pharma exploits US patients while charging far less abroad.
• There is sharp disagreement on whether the rest of the world is “free riding” on high US prices, or whether US market structure and intermediaries (insurers, PBMs, hospital systems) are the real problem.

Access, Insurance, and Obesity as a Condition

• Multiple people describe being denied coverage for branded GLP‑1s unless already diabetic, facing list prices near $1,000/month, and turning to compounders at ~$100–250/month with dramatic health improvements.
• Others say prices have fallen (e.g., ~$200–500/month direct from manufacturers) but still see insurers excluding drugs for “just” obesity.
• There’s tension between views that obesity is largely self‑inflicted and should not raise everyone’s premiums, versus seeing overeating as akin to addiction, often linked to mental health and biology, making GLP‑1s cost‑effective preventative care.

Safety, Quality, and “Wild West” Supply Chains

• Defenders of FDA action highlight:
  • Compounders sourcing peptide APIs from lightly overseen Chinese manufacturers.
  • Variable processes, excipients, and documented dosing/allergic issues.
  • Higher inherent risks in small‑batch compounding vs validated industrial lines.
• Others claim reputable compounders and “research chem” vendors often use third‑party HPLC, sterility, and impurity testing, sometimes more transparently than pharmacies, and see little evidence of serious harm so far.

Regulatory Design, Alternatives, and Workarounds

• Several note FDA’s mandate is safety/efficacy, not affordability or insurance coverage; by that lens, once brand supply stabilized, compounding exemptions had to go.
• Critics say this binary approved/unapproved model fails in cases like GLP‑1s where unmet need and price are huge, suggesting:
  • Government patent buyouts or state‑funded R&D.
  • International treaties to share development costs.
  • Price‑linking rules (US can’t be charged far more than other countries), though others argue this would reduce global innovation.

Grey/Black Markets and Unintended Consequences

• Many expect enforcement to push demand further underground:
  • Direct import of lyophilized peptides from overseas via Telegram/Discord and crypto.
  • Local “guy with a freezer” replacing semi‑regulated compounders, arguably lowering safety.
• Some think this “Wild West” biohacking equilibrium—tight FDA control for most people, underground access for risk‑tolerant users—is already here and will persist.

Politics and Geopolitics

• A subset attributes timing to lobbying and Trump‑era drug‑pricing politics, including trade deals and MFN‑style pricing rhetoric, though details and real effects of such policies are contested.
• There is also discussion of India and other countries ramping GLP‑1 generics as patents lapse or aren’t enforced, likely driving very low global prices long before US patents expire.